Infinity Pharmaceuticals Inc. (INFI)

1.16
NASDAQ : Health Technology
Prev Close 1.17
Day Low/High 1.13 / 1.20
52 Wk Low/High 1.00 / 2.92
Avg Volume 79.40K
Exchange NASDAQ
Shares Outstanding 57.03M
Market Cap 66.72M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock

Trade-Ideas: Infinity Pharmaceuticals (INFI) Is Today's Strong On High Relative Volume Stock

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Infinity Provides Company Update And Reports Second Quarter 2015 Financial Results

Infinity Provides Company Update And Reports Second Quarter 2015 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2015 financial results and ongoing progress with duvelisib an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and...

Infinity Announces The Date Of Its Second Quarter 2015 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its Second Quarter 2015 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Thursday, August 6, 2015, at 8:30 a.

Infinity Pharmaceuticals Enters Oversold Territory (INFI)

Infinity Pharmaceuticals Enters Oversold Territory (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Infinity To Participate In Two Upcoming Conferences

Infinity To Participate In Two Upcoming Conferences

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will participate in two upcoming investor conferences.

10 Worst Biotech Stocks in the NASDAQ

10 Worst Biotech Stocks in the NASDAQ

Some biotech stocks way underperformed in this red-hot sector.

Commit To Purchase Infinity Pharmaceuticals At $9, Earn 14.9% Annualized Using Options

Commit To Purchase Infinity Pharmaceuticals At $9, Earn 14.9% Annualized Using Options

Investors considering a purchase of Infinity Pharmaceuticals Inc stock, but tentative about paying the going market price of $11.06/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $9 strike, which has a bid at the time of this writing of 75 cents.

RSI Alert: Infinity Pharmaceuticals (INFI) Now Oversold

RSI Alert: Infinity Pharmaceuticals (INFI) Now Oversold

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Infinity Reports Phase 1 Data Showing Clinical Activity Of Duvelisib In Treatment-Naïve Patients With Chronic Lymphocytic Leukemia

Infinity Reports Phase 1 Data Showing Clinical Activity Of Duvelisib In Treatment-Naïve Patients With Chronic Lymphocytic Leukemia

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) today announced new clinical data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with...

Infinity To Participate In Three Investor Conferences In June

Infinity To Participate In Three Investor Conferences In June

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following three upcoming conferences: Jefferies Global Healthcare Conference, New York, June 3 rd , at 4:30 p.

Infinity Reports Preclinical Data For Duvelisib Demonstrating Synergy With Standard-of-Care Therapies And Emerging Agents In Development For The Treatment Of Hematologic Malignancies

Infinity Reports Preclinical Data For Duvelisib Demonstrating Synergy With Standard-of-Care Therapies And Emerging Agents In Development For The Treatment Of Hematologic Malignancies

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) today announced new preclinical data for duvelisib (IPI-145), an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma.

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Strong On High Volume: Infinity Pharmaceuticals (INFI)

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a strong on high relative volume candidate

Today's Weak On High Volume Stock: Infinity Pharmaceuticals (INFI)

Today's Weak On High Volume Stock: Infinity Pharmaceuticals (INFI)

Trade-Ideas LLC identified Infinity Pharmaceuticals (INFI) as a weak on high relative volume candidate

Infinity Announces New Data For Duvelisib To Be Presented At The 2015 American Society Of Clinical Oncology Annual Meeting

Infinity Announces New Data For Duvelisib To Be Presented At The 2015 American Society Of Clinical Oncology Annual Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the upcoming poster presentations of new clinical, translational and preclinical data with  duvelisib (IPI-145), an oral, dual inhibitor...

Oversold Conditions For Infinity Pharmaceuticals (INFI)

Oversold Conditions For Infinity Pharmaceuticals (INFI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Infinity Reports First Quarter 2015 Financial Results And Recent Corporate Developments

Infinity Reports First Quarter 2015 Financial Results And Recent Corporate Developments

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2015 financial results and ongoing progress with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and...

Infinity To Participate In Three Conferences In May

Infinity To Participate In Three Conferences In May

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the following three upcoming conferences: Deutsche Bank Securities 40 th Annual Health Care Conference, Boston, May 7 th, at 1:30 p.

Infinity Announces The Date Of Its First Quarter 2015 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its First Quarter 2015 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Wednesday, May 6, 2015, at 8:30 a.

Infinity Reports Preclinical Data For Duvelisib In Combination With Venetoclax At The 2015 American Association For Cancer Research Annual Meeting

Infinity Reports Preclinical Data For Duvelisib In Combination With Venetoclax At The 2015 American Association For Cancer Research Annual Meeting

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the presentation of new preclinical and translational data for duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta...

Sujay Kango, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)

Sujay Kango, Executive Vice President, Chief Commercial Officer (Photo: Business Wire)

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that Sujay Kango has joined the company as executive vice president, chief commercial officer and Winston "K.

Notable Two Hundred Day Moving Average Cross - INFI

Notable Two Hundred Day Moving Average Cross - INFI

In trading on Wednesday, shares of Infinity Pharmaceuticals Inc crossed below their 200 day moving average of $13.78, changing hands as low as $13.52 per share. Infinity Pharmaceuticals Inc shares are currently trading down about 0.8% on the day.

Infinity Exercises Option To Buy Out All Future Royalty Obligations To Takeda For Duvelisib Sales In Oncology

Infinity Exercises Option To Buy Out All Future Royalty Obligations To Takeda For Duvelisib Sales In Oncology

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it has exercised its option to buy out all future royalty obligations due to Takeda Pharmaceutical Company Limited for sales of duvelisib (IPI-145),...

Commit To Purchase Infinity Pharmaceuticals At $10, Earn 7.4% Annualized Using Options

Commit To Purchase Infinity Pharmaceuticals At $10, Earn 7.4% Annualized Using Options

Investors eyeing a purchase of Infinity Pharmaceuticals Inc stock, but tentative about paying the going market price of $15.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $10 strike, which has a bid at the time of this writing of 60 cents.

Infinity Pharmaceuticals (INFI) Downgraded From Hold to Sell

Infinity Pharmaceuticals (INFI) Downgraded From Hold to Sell

Infinity Pharmaceuticals (INFI) has been downgraded by TheStreet Ratings from Hold to Sell with a ratings score of D.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AKRX, BIO, BIO.B, GSK, HCKT, MDRX, NLNK, QLTY, STLY, TPC, TTMI Downgrades: BWC, DRYS, HAWK, HSC, INFI, LGCY, MG, NATR, NTLS, ZEUS Initiations: EVGN, MEG Read on to get TheStreet Quant Ratings' detailed report:

Infinity Provides Company Update And Reports Full-Year 2014 Financial Results

Infinity Provides Company Update And Reports Full-Year 2014 Financial Results

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full-year 2014 financial results and ongoing progress with duvelisib (IPI-145), an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and...

Infinity To Present At The RBC Capital Markets 2015 Healthcare Conference

Infinity To Present At The RBC Capital Markets 2015 Healthcare Conference

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be presenting at the RBC Capital Markets 2015 Healthcare Conference on February 25, 2015, at 3:35 p.

Infinity Announces The Date Of Its Full-Year 2014 Financial Results Conference Call And Webcast

Infinity Announces The Date Of Its Full-Year 2014 Financial Results Conference Call And Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Tuesday, February 24, 2015, at 4:30 p.

Infinity Provides Key 2015 Goals And Financial Guidance

Infinity Provides Key 2015 Goals And Financial Guidance

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its anticipated pipeline goals and provided financial guidance for 2015.

Infinity Reports Topline Results From Phase 2 Study Of Duvelisib In Rheumatoid Arthritis

Infinity Reports Topline Results From Phase 2 Study Of Duvelisib In Rheumatoid Arthritis

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background methotrexate in patients...

TheStreet Quant Rating: D (Sell)